Biogen IDs patients at highest risk of PML; Abbott's Norvir-pricing settlement pegged at $52M;

@FiercePharma: GSK to shed 19 products in consumer refocus. Article | Follow @FiercePharma

> Biogen Idec has identified high-risk patients taking its multiple sclerosis drug Tysabri who have a 1 in 100 chance of developing a potentially deadly brain infection from the medicine. Report

> Pozen said a federal court has granted a preliminary injunction ordering Par Pharmaceutical not to develop and sell a generic version the migraine drug Treximet. Story

> Abbott Laboratories has agreed to pay $52 million when it resolved claims by direct drug purchasers that it tried to harm competition when it quadrupled the price of its HIV medicine Norvir in 2003. News

> Valeant Pharmaceuticals has added Abe Friedman, BlackRock's former corporate governance chief, to a proposed slate of directors to replace Cephalon's board. Item

> Taconic Capital Advisors has accumulated a 7.46 percent stake in U.S. drugmaker Cephalon, subject of a $5.7 billion takeover bid from Valeant Pharmaceuticals. Article

> India's Strides Arcolab said it has received approval from the U.S. FDA for its new injectables manufacturing facility in Bangalore. Report

> The FDA has approved Roche's Actemra (tocilizumab), given alone or in combination with methotrexate, to treat active systemic juvenile idiopathic arthritis in children ages 2 years and older. FDA release

> Aurobindo Pharma has won final FDA approval to market its generic version of extended release Effexor, a Wyeth antidepressant, in multiple strengths. News

> China was asked by Brazil, Russia, India and South Africa to buy more of their value-added products, with a particular reference to Indian pharmaceuticals. Item

> Takeda Pharmaceutical launched its hypertension drug Edarbi, an angiotensin receptor blocker, in the U.S. market. Story

> Indian pharma companies are being encouraged to set up manufacturing facilities in Kazakhstan through joint ventures. Report

Biotech News

 @FierceBiotech: Galapagos ditches its experimental arthritis drug. Item | Follow @FierceBiotech

 @JohnCFierce: Here's the Reuters story on the tofacitinib RA data for Pfizer. Hard to overestimate importance for Pfizer. Story | Follow @JohnCFierce

> Amarin shares skyrocket as lead drug clears second Ph3. Report 

> CoDa banks $19M round for mid-stage wound healing study. Story 

> Regulators hand Eli Lilly another new drug rejection. Item 

> Skeptical investors demanding R&D strategy, dividends at Amgen meeting. Article 

Biotech IT News

> Roche informatics guru tackles complex data. News 

> Online brain atlas offers clues about diseases. Article 

> What's driving low enrollment in trials? Report

> "Open source biology" takes center stage. Item 

> Study: Paperless clinical trials offer advantages. News 

Medical Devices News

> Benvenue closes $35.5M round of financing. Report

> Rotation Medical, Dgimed Ortho, raise combined $12.1 million. Story 

> Boston Sci cuts jobs in MN. Article 

> J&J in talks to buy Synthes for $20 billion. News 

> AZ begins Astra Tech auction. Report 

> Medtronic invests $7M in Tengion. Item 

> Lucid files for IPO as it looks to repay debt. Story

And Finally... The Virginia attorney general challenging President Barack Obama's healthcare overhaul is quick to agree that his request for fast-track review by the U.S. Supreme Court is a long shot. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.